Novartis names Klaus Moosmayer ethics, risk, and compliance chief

Moosmayer is set to join the pharma company in December.

Healix's Jeffrey Erb on what pharma giants consolidating accounts means for agencies

Bigger budgets, fewer accounts. That's the dilemma facing pharma marketers as drugmakers consolidate work.

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Q&A: Matt McNally on the road ahead for Outcome Health and the state of the POC union

Matt McNally, CEO of Outcome Health, shares his thoughts on post-controversy Outcome Health and the overall state of the point-of-care union.

Media buyers form group to advance standards in POC

Media buyers form group to advance standards in POC

Among the group's members are media agencies that had pulled healthcare ad spend from the POC channel in the wake of a scandal 10 months ago.

POC community makes good on promises of transparency and accountability

POC community makes good on promises of transparency and accountability

After a scandal with one of point of care's biggest players, we examine how the community is living up to its promise of greater transparency.

Five things for pharma marketers to know: Tuesday, August 14, 2018

Five things for pharma marketers to know: Tuesday, August 14, 2018

Icahn drops bid to stop Cigna-Express Scripts tie-up; Bayer joins Evotec-Haplogen partnership to find COPD treatments; Orchard raises $150 million in Series C funding.

WPP leaves Farm Street HQ as it cuts links with Sorrell era

WPP leaves Farm Street HQ as it cuts links with Sorrell era

WPP is set to depart its London headquarters in Farm Street after more than 30 years as it seeks "a more modern and attractive office."

Novartis ups Sreejit Mohan to global head of external communications

Novartis ups Sreejit Mohan to global head of external communications

Mohan was previously head of global drug-development communications.

Five things for pharma marketers to know: Monday, August 13, 2018

Five things for pharma marketers to know: Monday, August 13, 2018

Bayer shares fall after Monsanto weedkiller judgment; FDA approves first birth-control app to be marketed as contraception method; Regulators okay landmark RNAi-based therapy.

Marketing a first-of-its-kind addiction treatment amid the opioid crisis

Marketing a first-of-its-kind addiction treatment amid the opioid crisis

The first non-opioid opioid-withdrawal treatment, Lucemyra, hit the market this week.

Five things for pharma marketers to know: Friday, August 10, 2018

Five things for pharma marketers to know: Friday, August 10, 2018

FDA approves record number of generics in July; Trump drug-pricing policies may be hurting generic makers; Justice Department joins opioid lawsuit.

Outcome Health adds Nielsen measurement tools

Outcome Health adds Nielsen measurement tools

The point-of-care healthcare marketing company also conducted an initial study with Nielsen on its audience.

Five things for pharma marketers to know: Thursday, August 9, 2018

Five things for pharma marketers to know: Thursday, August 9, 2018

Rite Aid, Albertsons call off merger; AMA disapproves of CVS-Aetna deal; FDA signs off on first generic drug for CGT designation.

Kyne partners with Agora to expand reach to Latin America

Kyne partners with Agora to expand reach to Latin America

The partnership will give Kyne a presence in Mexico, Argentina, and Colombia.

Five things for pharma marketers to know: Wednesday, August 8, 2018

Five things for pharma marketers to know: Wednesday, August 8, 2018

Trump promises move to lower drug prices; CVS, Novo Nordisk beat earnings predictions; AstraZeneca settles two suits with Texas for $110 million.